Barr and Bayer Sign Supply and Licensing Agreements for Launch of Generic Yasmin(R) and Yaz(R) Oral Cont... (ration's Orange Book. Barr will pay Baye...)

Barr and Bayer Sign Supply and Licensing Agreements for Launch of Generic Yasmin(R) and Yaz(R) Oral Contraceptives

Date:6/23/2008

ration's Orange Book. Barr will pay Bayer an undisclosed supply price for the product. Barr also has an additional undisclosed profit split with Gedeon Richter, its development partner for generic Yasmin.

Yaz Supply and Licensing Agreement

Under a separate agreement, Bayer will supply Barr with an authorized generic version of Yaz for launch on July 1, 2011, or earlier in certain circumstances. Barr will pay Bayer an undisclosed supply price for the product. Barr also has an additional undisclosed profit split with Gedeon Richter, its development partner for generic Yaz.

Ongoing Yasmin Patent Litigation

On March 3, 2008 Barr announced that the U.S. District Court for the District of New Jersey had ruled in favor of its subsidiary, Barr Laboratories, Inc., in the challenge of the patent listed by Bayer's Yasmin product. On April 1, 2008, Bayer appealed this ruling to the U.S. Court of Appeals for the Federal Circuit. Under the licensing agreements, Barr will continue to be able to sell generic versions of Yasmin and Yaz regardless of the outcome of Bayer's appeal.

Yasmin provides an oral contraceptive regimen consisting of 21 active tablets each containing 3 mg of drospirenone and 0.03 mg of ethinyl estradiol and 7 inert tablets. Yasmin is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive. The product had annual U.S. sales of approximately $575 million for the twelve months ended April 2008, based on IMS sales data.

Yaz provides an oral contraceptive regimen consisting of 24 active tablets each containing 3 mg of drospirenone and 0.02 mg of ethinyl estradiol and 4 inert tablets. Yaz is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive. The product had annual U.S. sales of approximately $384 million for the twelve months ended April 2008, based on IMS sales data.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global
'/>"/>

0

GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Statement From Bayer(R) Aspirin Regarding the American Medical Associations New Aspirin Policy Resolution
2. Bayer Announces Availability of Reformulated Liquid Leukine(R)
3. ACT Biotech Acquires Clinical and Early Stage Oncology Portfolio Licenses From Bayer Healthcare
4. United Nations Environment Programme and Bayer Corporation Announce North American Winners of International Childrens Painting Competition
5. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
6. Bayer HealthCare Pharmaceuticals, Amerinet Extend Contrast Media Agreement
7. Bayer to Receive Two Top National Awards for Its Science Education, Science Literacy Work
8. Bayer HealthCare and Juvaris BioTherapeutics Announce Major Licensing Agreement
9. 60 Minutes to Report on Dangers of Trasylol: Cory Watson Crowder & DeGaris Involved in Litigation Against Pharmaceutical Giant Bayer AG
10. Bayer Establishes US Special Access Program for Leukine(R) While Replacing Current Liquid Formulation
11. Bayer Corporation Renames Its U.S. Foundation, Refocuses Charitable Giving Areas

Post Your Comments:

Barr and Bayer Sign Supply and Licensing Agreements for Launch of Generic Yasmin(R) and Yaz(R) Oral Cont...(ration's Orange Book. Barr will pay Baye...),Health